LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,089
تعداد مقالات9,995
تعداد مشاهده مقاله26,434,174
تعداد دریافت فایل اصل مقاله7,285,535
Pourmand, Daryoush, Veisi-Raygani, Asad, Bahrehmand, Fariborz, Asadi, Soheila. (1402). The Association between Apolipoprotein E Genotypes and Serum Malondialdehyde Level with End-Stage Renal Disease. سامانه مدیریت نشریات علمی, 48(4), 414-419. doi: 10.30476/ijms.2022.94850.2616
Daryoush Pourmand; Asad Veisi-Raygani; Fariborz Bahrehmand; Soheila Asadi. "The Association between Apolipoprotein E Genotypes and Serum Malondialdehyde Level with End-Stage Renal Disease". سامانه مدیریت نشریات علمی, 48, 4, 1402, 414-419. doi: 10.30476/ijms.2022.94850.2616
Pourmand, Daryoush, Veisi-Raygani, Asad, Bahrehmand, Fariborz, Asadi, Soheila. (1402). 'The Association between Apolipoprotein E Genotypes and Serum Malondialdehyde Level with End-Stage Renal Disease', سامانه مدیریت نشریات علمی, 48(4), pp. 414-419. doi: 10.30476/ijms.2022.94850.2616
Pourmand, Daryoush, Veisi-Raygani, Asad, Bahrehmand, Fariborz, Asadi, Soheila. The Association between Apolipoprotein E Genotypes and Serum Malondialdehyde Level with End-Stage Renal Disease. سامانه مدیریت نشریات علمی, 1402; 48(4): 414-419. doi: 10.30476/ijms.2022.94850.2616

The Association between Apolipoprotein E Genotypes and Serum Malondialdehyde Level with End-Stage Renal Disease

Iranian Journal of Medical Sciences
مقاله 8، دوره 48، شماره 4، مهر 2023، صفحه 414-419    اصل مقاله (317.48 K)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/ijms.2022.94850.2616
نویسندگان
Daryoush Pourmand1؛ Asad Veisi-Raygani2؛ Fariborz Bahrehmand3؛ Soheila Asadi* 1
1Department of Laboratory Sciences, School of Para Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran
2Department of Clinical Biochemistry, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran
3Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
چکیده
Background: The Apolipoprotein E (ApoE) polymorphism plays an important role in the pathophysiology of end-stage renal disease (ESRD). Additionally, ApoE may contribute to the progression of oxidative stress. Thus, this study aimed to determine the ApoE gene polymorphism and evaluate the malondialdehyde (MDA) level in ESRD patients and healthy individuals.
Methods: The present cross-sectional study was conducted at 2010 at Kermanshah University of Medical Sciences (Kermanshah, Iran). The study population comprised ESRD patients (n=136) and healthy individuals (n=137). The MDA level was assessed using high-performance liquid chromatography (HPLC), and the frequencies of ApoE gene alleles were analyzed using restriction fragment length polymorphism-polymerase chain reaction (RFLP-PCR). The data were analyzed using Statistical Package for Social Sciences (SPSS), version 13. The significant differences of ApoE genotypes in case and control groups were assessed using Pearson’s Chi square tests, and two-tailed Student’s tests. A logistic regression model was used to calculate the odd ratio. P<0.05 was considered statistically significant. 
Results: According to the results, ESRD patients had a higher frequency of the E2/E3 genotype than the healthy group (P<0.001). The results indicated that E3/E4 genotype frequency in the patients’ group was higher than that of the control group (P=0.026). Furthermore, the  E3/E2 (OR=5.7, 95% CI=2.68-12.14) (P<0.001) and E3/E4 (OR=1.57, 95% CI=1.05-2.34) (P=0.029) genotypes were found to increase the risk of ESRD. Moreover, the MDA level in ESRD patients was higher than the healthy individuals (P<0.001). The patients with E3/E2 (P<0.001) and E3/E4 (P<0.001) genotypes had a higher level of MDA than the control group. 
Conclusion: According to the findings, patients with ESRD had higher genotypes of E3/E2 and E3/E4, which suggests a higher risk of developing ESRD. 
کلیدواژه‌ها
Kidney Failure, Chronic؛ Apolipoproteins E؛ Malondialdehyde؛ Polymorphism
سایر فایل های مرتبط با مقاله
مراجع
  1. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382:260-72. doi: 10.1016/S0140-6736(13)60687-X. PubMed PMID: 23727169.
  2. De Nicola L, Donfrancesco C, Minutolo R, Lo Noce C, De Curtis A, Palmieri L, et al. [Epidemiology of chronic kidney disease in Italy: current state and contribution of the CARHES study]. G Ital Nefrol. 2011;28:401-7. PubMed PMID: 21809309.
  3. Wen CP, Cheng TY, Tsai MK, Chang YC, Chan HT, Tsai SP, et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet. 2008;371:2173-82. doi: 10.1016/S0140-6736(08)60952-6. PubMed PMID: 18586172.
  4. Lahrach H, Essiarab F, Timinouni M, Hatim B, El Khayat S, Er-Rachdi L, et al. Association of apolipoprotein E gene polymorphism with end-stage renal disease and hyperlipidemia in patients on long-term hemodialysis. Ren Fail. 2014;36:1504-9. doi: 10.3109/0886022X.2014.949760. PubMed PMID: 25155022.
  5. Araki S, Moczulski DK, Hanna L, Scott LJ, Warram JH, Krolewski AS. APOE polymorphisms and the development of diabetic nephropathy in type 1 diabetes: results of case-control and family-based studies. Diabetes. 2000;49:2190-5. doi: 10.2337/diabetes.49.12.2190. PubMed PMID: 11118024.
  6. Rall SC, Jr., Weisgraber KH, Mahley RW. Human apolipoprotein E. The complete amino acid sequence. J Biol Chem. 1982;257:4171-8. PubMed PMID: 7068630.
  7. Weisgraber KH, Rall SC, Jr., Mahley RW. Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem. 1981;256:9077-83. PubMed PMID: 7263700.
  8. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622-30. doi: 10.1126/science.3283935. PubMed PMID: 3283935.
  9. Jofre-Monseny L, Minihane AM, Rimbach G. Impact of apoE genotype on oxidative stress, inflammation and disease risk. Mol Nutr Food Res. 2008;52:131-45. doi: 10.1002/mnfr.200700322. PubMed PMID: 18203129.
  10. Song Y, Stampfer MJ, Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med. 2004;141:137-47. doi: 10.7326/0003-4819-141-2-200407200-00013. PubMed PMID: 15262670.
  11. Eto M, Saito M, Okada M, Kume Y, Kawasaki F, Matsuda M, et al. Apolipoprotein E genetic polymorphism, remnant lipoproteins, and nephropathy in type 2 diabetic patients. Am J Kidney Dis. 2002;40:243-51. doi: 10.1053/ajkd.2002.34502. PubMed PMID: 12148096.
  12. Innerarity TL, Weisgraber KH, Arnold KS, Rall SC, Jr., Mahley RW. Normalization of receptor binding of apolipoprotein E2. Evidence for modulation of the binding site conformation. J Biol Chem. 1984;259:7261-7. PubMed PMID: 6327714.
  13. Hatters DM, Peters-Libeu CA, Weisgraber KH. Apolipoprotein E structure: insights into function. Trends Biochem Sci. 2006;31:445-54. doi: 10.1016/j.tibs.2006.06.008. PubMed PMID: 16820298.
  14. Srinivasan SR, Radhakrishnamurthy B, Vijayagopal P, Berenson GS. Proteoglycans, lipoproteins, and atherosclerosis. Adv Exp Med Biol. 1991;285:373-81. doi: 10.1007/978-1-4684-5904-3_45. PubMed PMID: 1858569.
  15. Saito T, Sato H, Oikawa S, Kudo K, Kurihara I, Nakayama K, et al. Lipoprotein glomerulopathy. Report of a normolipidemic case and review of the literature. Am J Nephrol. 1993;13:64-8. doi: 10.1159/000168591. PubMed PMID: 8322843.
  16. Storz G, Imlay JA. Oxidative stress. Curr Opin Microbiol. 1999;2:188-94. doi: 10.1016/s1369-5274(99)80033-2. PubMed PMID: 10322176.
  17. Finaud J, Lac G, Filaire E. Oxidative stress : relationship with exercise and training. Sports Med. 2006;36:327-58. doi: 10.2165/00007256-200636040-00004. PubMed PMID: 16573358.
  18. Talmud PJ, Stephens JW, Hawe E, Demissie S, Cupples LA, Hurel SJ, et al. The significant increase in cardiovascular disease risk in APOEepsilon4 carriers is evident only in men who smoke: potential relationship between reduced antioxidant status and ApoE4. Ann Hum Genet. 2005;69:613-22. doi: 10.1111/j.1529-8817.2005.00205.x. PubMed PMID: 16266401.
  19. Pham T, Kodvawala A, Hui DY. The receptor binding domain of apolipoprotein E is responsible for its antioxidant activity. Biochemistry. 2005;44:7577-82. doi: 10.1021/bi0472696. PubMed PMID: 15896001.
  20. Jofre-Monseny L, de Pascual-Teresa S, Plonka E, Huebbe P, Boesch-Saadatmandi C, Minihane AM, et al. Differential effects of apolipoprotein E3 and E4 on markers of oxidative status in macrophages. Br J Nutr. 2007;97:864-71. doi: 10.1017/S0007114507669219. PubMed PMID: 17381973.
  21. Cofan F, Cofan M, Rosich E, Campos B, Casals E, Zambon D, et al. Effect of apolipoprotein E polymorphism on renal transplantation. Transplant Proc. 2007;39:2217-8. doi: 10.1016/j.transproceed.2007.06.011. PubMed PMID: 17889142.
  22. Oda H, Yorioka N, Ueda C, Kushihata S, Yamakido M. Apolipoprotein E polymorphism and renal disease. Kidney Int Suppl. 1999;71:S25-7. doi: 10.1046/j.1523-1755.1999.07107.x. PubMed PMID: 10412731.
  23. Onuma T, Laffel LM, Angelico MC, Krolewski AS. Apolipoprotein E genotypes and risk of diabetic nephropathy. J Am Soc Nephrol. 1996;7:1075-8. doi: 10.1681/ASN.V771075. PubMed PMID: 8829124.
  24. Hubacek JA, Bloudickova S, Kubinova R, Pikhart H, Viklicky O, Bobak M. Apolipoprotein E polymorphism in hemodialyzed patients and healthy controls. Biochem Genet. 2009;47:688-93. doi: 10.1007/s10528-009-9266-y. PubMed PMID: 19565203; PubMed Central PMCID: PMCPMC3951864.
  25. Nomani H, Khanmohamadian H, Vaisi-Raygani A, Shakiba E, Tanhapour M, Rahimi Z. Chemerin rs17173608 and vaspin rs2236242 gene variants on the risk of end stage renal disease (ESRD) and correlation with plasma malondialdehyde (MDA) level. Ren Fail. 2018;40:350-6. doi: 10.1080/0886022X.2018.1459698. PubMed PMID: 29644922; PubMed Central PMCID: PMCPMC6014516.
آمار
تعداد مشاهده مقاله: 519
تعداد دریافت فایل اصل مقاله: 398


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب